HOME >> MEDICINE >> NEWS
Other highlights in the March 2 JNCI

ol of Public Health in Minneapolis, discusses two novel aspects of this study--comparing the offer of an explicit choice between screening tests to recommendations of a specific test and to the option of doing both tests, and comparing two methods of distributing the FOBT kits. He questions whether theoretical models of screening behavior would predict the surprising finding that subjects who were given a choice between screening methods did not have a higher screening participation rate than subjects who were not given a choice.

Contacts:

  • Article: Nereo Segnan, Centro Prevenzione Oncologica Regione Piemonte and Azienda Sanitaria Ospedaliera S Giovanni Battista, +390116333860, nereo.segnan@cpo.it
  • Editorial: Molly Portz, Media Relations, University of Minnesota, 612-625-2640, mportz@umn.edu

    Tamoxifen's Association With Endometrial Cancer Risk in Pre- and Postmenopausal Women Examined

    Tamoxifen use is associated with an increased risk of endometrial cancer. A new study has found that this risk is similar in pre- and postmenopausal women, increases with duration of use, and does not diminish through 5 years of follow-up after the treatment ends.

    Anthony J. Swerdlow, D.Sc., of the Institute of Cancer Research in Sutton, England, and colleagues conducted a casecontrol study in Britain of 813 patients who had endometrial cancer following breast cancer diagnosis and 1,067 control subjects who had breast cancer but not subsequent endometrial cancer.

    Overall, tamoxifen treatment was associated with 2.4 times the risk of endometrial cancer compared with no treatment. The risk increased with the duration of treatment and did not diminish in the 5 years following the end of treatment. The risk was similar in pre- and postmenopausal women. The authors write that, until further data are available, their results "suggest that the associated ris
    '"/>



  • Contact: Sarah L. Zielinski
    jncimedia@oupjournals.org
    301-841-1287
    Journal of the National Cancer Institute
    1-Mar-2005


    Page: 1 2 3 4

    Related medicine news :

    1. Other highlights in the March 16 JNCI
    2. Other highlights in the February 2 JNCI
    3. Other highlights in the January 19 JNCI
    4. Other highlights in the December 15 JNCI
    5. Other highlights in the December 1 JNCI
    6. Other highlights in the September 15 JNCI
    7. Other highlights in the April 21 JNCI
    8. Other highlights in the April 7 JNCI
    9. Other highlights in the January 7 issue of JNCI
    10. Other highlights in the December 3 issue of JNCI
    11. Other highlights in the November 19 issue of JNCI

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, ... the first in a new class of photodynamic cosmetics (PDC). , Allumera® is ... visibly reduce outward signs of aging, and minimize the appearance of pores – ...
    (Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges ... for how his administration could impact the employee benefits industry. James Slotnick, AVP, ... most likely to make it through Congress. His discussion will focus on the ...
    (Date:4/25/2017)... ... April 25, 2017 , ... As ... contracted partners to help with process innovation in drug formulation and manufacturing. ... along with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
    (Date:4/25/2017)... Clara, CA (PRWEB) , ... April 25, 2017 ... ... announces the addition of predictive analytics to its patient care management module. Using ... compliance even before a patient has been initiated on continuous positive airway pressure ...
    (Date:4/24/2017)... , ... April 24, 2017 , ... Emmanuel College ... busy nursing professionals advance their careers. Beginning in the fall of 2017, Emmanuel’s program ... degree in as few as 16 months and for as little as $14,528. These ...
    Breaking Medicine News(10 mins):
    (Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
    (Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
    (Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
    Breaking Medicine Technology:
    Cached News: